8-K
Cullinan Therapeutics, Inc. (CGEM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 25, 2021
CULLINAN ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39856 | 81-3879991 |
|---|---|---|
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |
| Cullinan Oncology, Inc. | ||
| --- | ||
| One Main Street, Suite 520 | ||
| Cambridge, MA 02142 | ||
| (Address of principal executive offices, including zip code) |
(617) 410-4650
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trade<br>Symbol(s) | Name of each exchange<br>on which registered |
|---|---|---|
| Common Stock, $0.0001 par value per share | CGEM | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
|---|
The Annual Meeting of Stockholders (the “Annual Meeting”) of Cullinan Oncology, Inc. (the “Company”) was held on June 25, 2021. The holders present voted on the two proposals presented at the Annual Meeting as follows.
Proposal One — Election of Directors
The Company’s stockholders elected two Class I directors to the Company’s Board of Directors for three-year terms or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, by the following votes:
| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Thomas Ebeling | 22,640,822 | 3,023,638 | 927,824 |
| Morana Jovan-Embiricos, Ph.D. | 23,203,691 | 2,460,769 | 927,824 |
Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2021 by the following votes:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 26,587,700 | 4,584 | 0 | 0 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CULLINAN ONCOLOGY, INC. | ||
|---|---|---|
| Dated: July 1, 2021 | By: | /s/ Jeffrey Trigilio |
| Jeffrey Trigilio | ||
| Chief Financial Officer |